fuzzyjr - The problem with shorting is that it is close to the most unleveraged risk you can take investing, especially a baby biotech. Think about shorting Amazon in 2003 at $4 a share and the having it go up to $3700. You could look at Apple the same year at $8 a share having it split 2 for 1, 7 for 1 and 4 for 1 and then going up to $170 a share. In the Apple story there were dividends to be paid as well beginning around 2013. No one in their right mind would be short those companies for that length of time but the example does show the extreme risk. Immunomedics went from $ .25 to $84 in about 3 years not all that long ago and that is something that could happen with this story if the moon and stars ever line up for this pig we are invested in.

tada